Potential therapeutic targets for the treatment of detrusor overactivity

Bibliography

• MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BIU Int. (2001) 87(9):760–766.
   Google Scholar
• STEWART W, HERZOG AR, WEIM A et al.: Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn. (2001) 20:406.
   Google Scholar
• DE GROAT WC: A neurologic basis for the overactive bladder. Urology (1997) 50(Suppl. 6A):36–52.
   Google Scholar
• •Review of the evidence for the neurogenic basis of detrusor overactivity.
   Google Scholar
• BRADING AF: A myogenic basis for the overactive bladder. Urology (1998) 50(Suppl. 6A):57–67.
   Google Scholar
• •Review of the evidence for the myogenic basis of detrusor overactivity.
   Google Scholar
• DRAKE MJ, HARVEY IJ, GILLESPIE JI:Autonomous activity in the isolated guinea pig bladder. Exp. Physiol (2002) 88:19–30.
   Google Scholar
• LISTON TG, PALFREY EL, RAIMBACH SJ, FRY CH: The effects of pH changes on human and ferret detrusor muscle function. Physic] (1991) 432:1–21.
   Google Scholar
• EWALT DH, HOWARD PS, BLYTH Bet al.: Is lamina propria matrix responsible for normal bladder compliance? Urol. (1992) 148:544–549.
   Google Scholar
• BAYLISS M, WU C, NEWGREEN D et al.:A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle from stable, obstructed and unobstructed bladders. J. Urol. (1999) 162:1833–1839.
   PubMed Web of Science ®Google Scholar
• SJOGREN C, ANDERSSON KE, HUSTED S et al.: Atropine resistance of transmurally stimulated isolated human bladder muscle. Urol. (1982) 128:1368–1371.
   Google Scholar
• HAWTHORN MH, CHAPPLE CR, COCK M, CHESS-WILLIAMS R: Urothelium-derived inhibitory factor(s) influences detrusor muscle contractility in vitro. Br. Pharinacol (2000) 129:416–419.
   Google Scholar
• ••First paper to show that the inhibitoryeffects of the urotheliurn are due to the release of a diffusible inhibitory factor.
   Google Scholar
• TEMPLEMAN L, CHAPPLE CR, CHESS-WILLIAMS R: Urothelium derived inhibitory factor and cross-talk among receptors in the trigone of the bladder of the pig. J. Urol. (2002) 167(2 Pt 1):742–745.
   Google Scholar
• SOMOGYI GT, DE GROAT WC: Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci. (1999) 64:411–418.
   PubMed Web of Science ®Google Scholar
• EGLEN RM, HEGDE SS, WATSON N: Muscarinic receptor subtypes and smooth muscle function. Pharinacol Rev (1996) 15:114–119.
   Google Scholar
• CHESS-WILLIAMS R, CHAPPLE CR, YAMANISHI T, YASUDA K, SELLERS SJ: The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharinacol (2002) 21(5-6):243–248.
   Google Scholar
• FETSCHER C, FLEICHMAN M, SCHMIDT M, KREGE S, MICHEL MC: M3 muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharinacol (2002) 136(5):641–643.
   PubMed Web of Science ®Google Scholar
• CHESS-WILLIAMS R: Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton. Autacoid Pharinacol (2002) 22:133–145.
   PubMedGoogle Scholar
• MATSUI M, MOTOMURA D, KARASAWA H et al: Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl. Acad. Sd. USA (2000) 97:9579–9584.
   PubMed Web of Science ®Google Scholar
• WANG P, LUTHIN GR, RUGGIERI MR: Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. Pharinacol Exp. Ther. (1995) 273:959–966.
   PubMed Web of Science ®Google Scholar
• GOEPEL M, WITTMANN A, ROBBEN H, MICHEL MC: Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol. Res. (1997) 25:199–206.
   PubMedGoogle Scholar
• HEGDE SS, CHOPPIN A, BONHAUS D at al.: Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharinacol (1997) 120:1409–1418.
   Google Scholar
• •Study showing the role of M2 receptors in regulating bladder function in vivo.
   Google Scholar
• YAMANISHI T, YASUDA K, CHAPPLE CR, CHESS-WILLIAMS R: The role of M2-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br. J. Pharinacol (2000) 131:1482–1488.
   PubMed Web of Science ®Google Scholar
• YAMANISHI T, CHAPPLE CR, YASUDA K, CHESS-WILLIAMS R: The role of M2-muscarinic receptor subtypes in mediating contraction of the pig bladder base following cyclic AMP elevation and/or selective M3-inactiviation. .1. [Ira (2002) 167:397–401.
   Google Scholar
• HEGDE SS, EGLEN RM: Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Set (1999) 64:419–428.
   PubMed Web of Science ®Google Scholar
• STENGEL PW, GOMEZA J, VVESS Jet al.:M2 and M4 receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. Pharmacol Exp. The]: (2000) 292:877–885.
   Google Scholar
• BRAVERMAN AS, LUTHIN GR, RUGGIERI MR: M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Jim. j Physiol Regal. Integr. Comp. Physiol (1998) 275:R1654–R1660.
   Google Scholar
• BRAVERMAN AS, LEGOS J, YOUNG W et al.: M2 receptors in genito-urinary smooth muscle pathology. Life Sci. (1999) 64:429–436.
   PubMedGoogle Scholar
• •Study demonstrating an enhanced role for M2 receptors in disease.
   Google Scholar
• ABRAMS P, FREEMAN R, ANDERSTROM C et al.: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. BIU Int. (1998) 81:801–810.
   Google Scholar
• APPELL RA: Clinical efficacy and safety oftolterodine in the treatment of overactive bladder: a pooled analysis. Urology (1997) 50(Suppl.):90–96.
   Google Scholar
• GILLBERG PG, SUNDQUIST S, NILVEBRANT L: Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Ear: .1. Pharmacol (1998) 349:285–292.
   Google Scholar
• NILVEBRANT L, ANDERSSON KE, GILLBERG PG et al.: Tolterodine - a new bladder selective antimuscarinic agent. Eur: Pharmacol (1997) 327:195–207.
   PubMed Web of Science ®Google Scholar
• NEWGREEN DT, ANDERSON CWP, CARTER AJ, NAYLOR AM: Darifenacin: a novel bladder-selective agent for urge incontinence. NeurouroL Urodyn. (1995) 14:95.
   Google Scholar
• YAMAMOTO T, HONBO T, TOKORO K et al.: General pharmacology of the new antimuscarinic compound vamicamide. Arzeimittelforschung Drugs Res. (1995) 45:1274–1284.
   PubMedGoogle Scholar
• CHAPPLE CR, ARANO P, BOSCH JHR et al.: YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled Phase II-dose finding study. Neurourol. Urodyn. (2002) 21 (Suppl.):381.
   Google Scholar
• ANDERSSON KE: Pharmacology of lowerurinary tract smooth muscles and penile erectile tissues. Pharmacol Rev (1993) 45:253–308.
   PubMed Web of Science ®Google Scholar
• LEVIN RM, RUGGIERI MR, WEIN AJ: Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding. .1. Urol. (1988) 139:844–848.
   PubMed Web of Science ®Google Scholar
• NERGARDH A, BOREUS LO, NAGLO AS: Characterization of the adrenergic 13-receptor in the urinary bladder of man and cat. Acta Pharmacol. Toxicol (1977) 40:14–21.
   PubMedGoogle Scholar
• LARSEN JJ: a- And B-adrenoceptors in thedetrusor muscle and bladder base of the pig and P-adrenoceptors in the detrusor muscle of man. Br. Pharmacol (1979) 65:215–222.
   PubMed Web of Science ®Google Scholar
• IGAWA Y, YAMAZAKI Y, TAKEDA H et al.: Functional and molecular biological evidence for a possible 33-adrenoceptor in the human detrusor muscle. Br: J. Pharmacol (1999) 126:819–825.
   Google Scholar
• •133-Adrenoceptors demonstrated to relax the human bladder.
   Google Scholar
• TAKEDA M, OBARA K, MIZUSAWA T et al.: Evidence for 133-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. .1. Pharmacol Exp. The]: (1999) 288(3):1367–1373.
   Google Scholar
• NOMIYA M, YAMAGUCHI O: A quantitative analysis of mRNA expression of al and P-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. Urol (2003) 170:649–653.
   Google Scholar
• IGAWA Y, YAMAZAMI Y, TAKEDA H et al.: Relaxation effects of isoproterenol and selective 133-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders.' Urol (2001) 165:240–244.
   PubMed Web of Science ®Google Scholar
• YAMANISHI T, CHAPPLE CR, YASUDA K, YOSHIDA Y, CHESS-WILLIAMS R: The role of 133-adrenoceptors in mediating relaxation of porcine detrusor muscle. Br. Pharmacol (2002) 135:129–134.
   PubMedGoogle Scholar
• IGAWA Y, YAMAZAKI Y, TAKEDA H et al: Relaxant effects of isoproterenol and selective 133-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. Urol (2001) 165(1):240–144.
   Google Scholar
• LIU SP, HORAN P, LEVIN RM: Effects of atropine, isoproterenol and propranolol on the rabbit bladder contraction induced by intra-arterial administration of acetylcholine and ATP Urol (1998) 160(5):1863–1866.
   Google Scholar
• BIRDER LA, NEALEN ML, KISS S et al.: P-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder. Neurosci. (2002) 22(18):8063–8070.
   Google Scholar
• GRUNEBERGER A: Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br. .1. Obstet. Cynaecol (1984) 91:275–278.
   Google Scholar
• NORLEN L, SUNDIN T, WAGGSTEIN F: Effect of P-adrenoceptor stimulation on the human bladder in vivo. Urol mt. (1978) 33:355–358.
   Google Scholar
• LINDHOLM P, LOSE G: Terbutaline Wricany0 in the treatment of female urge incontinence. Urol mt. (1988) 41:158–160.
   Google Scholar
• CASTLEDEN CM, MORGAN B: The effect of P-adrenoceptor agonists on urinary incontinence in the elderly. Br. .1. Clin. Pharmacol. (1980) 10:619–620.
   PubMedGoogle Scholar
• NAGLO AS, NERGARDH A, BOREUA LO: Influence of atropine and isoprenaline on detrusor hyperactivity in children with neurogenic bladder. Scandj Urol Nephrol (1981) 15:97–102.
   PubMed Web of Science ®Google Scholar
• TRUSS MC, UCKERT S, STEIF CG et al:Cyclic nucleotide phosophdiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol Res. (1996) 24:123–128.
   Google Scholar
• TRUSS MC, STEIF CG, UCKERT S et al:Initial clinical experience with the selective phosphodiesterase-1 isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World j Urol (2000) 18:439–443.
   PubMed Web of Science ®Google Scholar
• HOWE BB, HALTERMAN TJ, YOCHIM CL et al: ZENECA ZD6169: a novel KATp channel opener with in vivo selectivity for urinary bladder." Pharmacol Exp. Ther: (1995) 274:884–890.
   Google Scholar
• WOJDAN A, FREEDEN C, WOODS M et al.: Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. Pharmacol Exp. Ther: (1999) 289(3):1410–1418.
   PubMedGoogle Scholar
• GOPALAKRISHNAN M, WHITEAKER KL, MOLINARI EJ et al.: Characterisation of the ATP-sensitive potassium channels (KATO expressed in guinea pig bladder smooth muscle cells. Pharmacol Exp. Ther. (1999) 289:551–558.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE: Clinical pharmacology of potassium channel openers. Pharmacol Toxicol (1992) 70:244–254.
   PubMedGoogle Scholar
• MARTIN SW, RADLEY SC, CHESS-WILLIAMS R, CHAPPLE CR: Relaxant effects of potassium-channel openers on normal and hyperreflexic detrusor muscle. Br. Um] (1997) 80:405–413.
   Google Scholar
• ANDERSSON KE, APPELL R, CARDOZO LD et al: The pharmacological treatment of urinary incontinence. BIU Int. (1999) 84:923–947.
   Google Scholar
• CHESS-WILLIAMS R, MARTIN SW, KORSTANJE C, CHAPPLE CR: In vitro investigation of the bladder-vascular selectivity of levcromakalim and YM934 in human tissues. BIU Int. (1999) 83:1050–1054.
   Google Scholar
• BUTERA JA, ANTANE MM, ANTANE SA et al.: Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity. Med. Chem. (2000) 43(6):1187–1202.
   Google Scholar
• HU SL, FINK CA, KIM HS, LAPPE RW: Novel and potent BK channel openers: CGS 7181 and its analogs. Drug Dev. Res. (1997) 41:10–21.
   Web of Science ®Google Scholar
• SIEMER C, BUSHFIELD M, NEWGREEN D, GRISSMER S: Effects of NS 1608 on MaxiK channels in smooth muscle cells from urinary bladder. J. Membrane Biol. (2000) 173:57–66.
   PubMed Web of Science ®Google Scholar
• SHAKER HS, TU LM, KALFOPOULOS M et al: Hyperreflexia of the urinary bladder: possible role of the efferent function of the capsaicin sensitive primary afferents. J. Um/. (1998) 160(6 Pt 1):2232–2239.
   Google Scholar
• •The role of capsaicin-sensitive sensory nerves shown in the neurogenic overactive bladder.
   Google Scholar
• SMET PJ, MOORE KH, JONAVICIUS J: Distribution and colocalisation of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable urinary bladder. Lab. Invest. (1997) 77(1):37–49.
   PubMed Web of Science ®Google Scholar
• MAGGI CA, PATACCHINI R, ROVERO P GIACHETTI A: Tachykinin receptors and tachykinin receptor subtypes. Amon. Pharmacol (1993) 13:23–93.
   Google Scholar
• BUFFINGTON CA, WOLFE SA: High affinity binding sites for [3H]substance P in urinary bladders of cats with interstitial cystitis. Um] (1998) 160(2):605–611.
   Google Scholar
• OHMURA M, KONDO A, SAITO M: Response of isolated human neurogenic bladders to tachykinins. Um] hat. (1997) 59(4):221–225.
   Google Scholar
• TEMPLEMAN L, SELLERS DJ, CHAPPLE CR, ROSARIO DJ, HAY DP, CHESS-WILLIAMS R: Investigation of neurokinin-2 and -3 receptors in the human and pig bladder. RAI Int. (2003) 92:787–792.
   Google Scholar
• MAGGI CA, SANTICIOLI P, PATACCHINI R et al.: Contractile response of the human isolated urinary bladder to neurokinins: involvement of NK-2 receptors. Ear.' Pharmacol (1988) 145:335.
   PubMed Web of Science ®Google Scholar
• LECCI A, TRAMONTANA M, GIULIANI S, CRISCUOLI M, MAGGI CA: Effect of tachykinin NK2 receptor blockade on detrusor hyperreflexia induced by bacterial toxin in rats. Um] (1998) 160(1):206–209.
   Google Scholar
• SOMOGI GT, TANOWITZ M, DE GROAT WC: M1 muscarinic receptor-mediated facilitation of acetylcholine release in the rat urinary bladder.' Physiol (1994) 140:81–89.
   Google Scholar
• SOMOGYI GT, DE GROAT WC: Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci. (1999) 64(6-7):411–418.
   PubMed Web of Science ®Google Scholar
• •A review of the presynaptic mechanisms operating in the bladder.
   Google Scholar
• SOMOGYI GT, ZERNOVA GV, YOSHIYAMA M, YAMAMOTO T, DE GROAT WC: Frequency dependence of muscarinic facilitation of transmitter release in urinary bladder strips from neurally intact or chronic spinal cord transected rats. Br. Pharmacol (1998) 125(2):241–246.
   PubMedGoogle Scholar
• ALBERTS P: Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. Pharmacol Exp. Ther. (1995) 274:458–468.
   PubMedGoogle Scholar
• LEIPPOLD T, REITZ A, SCHURCH B: Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur: Um] (2003) 44:165–174.
   PubMed Web of Science ®Google Scholar
• CARPENTER FG: Motor responses of theresponse of the urinary bladder and skeletal muscle in botulinum toxin intoxicated rats. Physiol (1967) 1988:1–11.
   Google Scholar
• SCHURCH B, STOHRER M, KRAMER G et al.: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. Um] (2000) 164:692–697.
   Google Scholar
• •A large study showing the efficacy of Botox in the neurogenic overactive bladder.
   Google Scholar
• REITZ A, VON TOBEL J, STOHRER M et al.: European experience of 184 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence. Neurourol Urodyn. (2002) 21(4):427–428.
   Google Scholar
• WYNDAELE JJ, VAN DROMME SA: Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord (2002) 40(11):599–600.
   PubMed Web of Science ®Google Scholar
• GROSS J, KRAMER G, SCHURCH B et al.: Repeated injection of botulinum-A toxin in patients with neurogenic lower urinary tract dysfunction do not cause increased drug tolerance. Neurourol Urodyn. (2002) 21(4):386–387.
   Google Scholar
• SELLERS DJ, CHESS-WILLIAMS R, CHAPPLE CR: 5-HT-induced potentiation of cholinergic responses to electrical field stimulation in pig detrusor muscle. BIU Int. (2000) 86:714–718.
   Google Scholar
• CORSI M, PIETRA C, TOSON G, TRIST D, ARTIBANI W: Pharmacological analysis of 5-hydroxytryptamine effects on electrically-stimulated human isolated urinary bladder. Br. J. Pharmacol (1991) 104:719–725.
   PubMed Web of Science ®Google Scholar
• TONNINI M, MESSORI E, FRANCES CHETTI GP et al.: Characterisation of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br. J Pharinacol. (1994) 113:1–2.
   Google Scholar
• CANDURA SM, MESS ORI M, FRANCES CHETTI GP et al.: Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazoline and substituted benzamide agonists and antagonists. Br. Phannacol (1996) 118:1965–1970.
   Google Scholar
• CHAPPLE CR, RADLEY SC, MARTIN SW, SELLERS DJ, CHESS-WILLIAMS R: 5-HT-induced potentiation of cholinergic responses to field-stimulation in normal and neurogenic overactive human detrusor muscle. BIU Int. (2003). In Press.
   Google Scholar
• KASHIBA H, UEDA Y, SENBA E: Systemic capsaicin in the adult rat differentially affects gene expression for neuropeptides and neurotrophin receptors in primary sensory neurons. Neuroscience (1997) 76:299–312.
   PubMedGoogle Scholar
• FARKAS-SZALLASI T, LUNDBERG JM, VVEISENFELD-HALLIN Z et al: Increased levels of GMAP, UIP and nitric oxide synthase, and their mRNAs, in lumbar dorsal root ganglia of the rat following systemic resiniferatoxin treatment. Neuroreport (1995) 6:2230–2234.
   PubMedGoogle Scholar
• SZALLASI A, FARKAS-SZALLASI T, TUCKER JB et al.: Effects of systemic resiniferatoxin on substance P mRNA in rat dorsal root ganglia and substance P receptor mRNA in the spinal cord. Brain Res. (1999) 815:177–184.
   PubMed Web of Science ®Google Scholar
• DE GROAT WC, KAWATANI M, HISAMITSU T et al.: Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. Auton. Nerv. Syst. (1998) 30 (Suppl.):S71-S77. so.DE GROAT WC: A neurologic basis for the overactive bladder. Urology (1997) 50(Suppl. 6A):36–52.
   Google Scholar
• FOWLER CJ, JEWKES D, MCDONALD WI et al: Intravesical capsaicin for neurogenic bladder dysfunction. Lancet (1992) 339:1239.
   PubMed Web of Science ®Google Scholar
• CRUZ F, GUIMARAES M, SILVA C et al: Desensitization of bladder sensory fibres by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. Ural. (1997) 157:585–589.
   PubMedGoogle Scholar
• DE SEZE M, WIART L, FERRIERE JL et al.: Intravesical instillation of capsaicin in urology: a review of literature. Eur. Um]. (1999) 36:267–277.
   PubMedGoogle Scholar
• SZALLASI A, BLUMBERG PM: Resiniferatwdn, a phorbol-related diterpene, acts as an ultrapotent analogue of capsaicin, the irritant constituent of red pepper. Neurosciences (1989) 30:515–520.
   PubMed Web of Science ®Google Scholar
• CRUZ F, GUIMARAES M, SILVA C et al:Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet (1997) 350:640–641.
   PubMed Web of Science ®Google Scholar
• SILVA C, RIO ME, CRUZ F: Desensitization of bladder sensory fibres by intravesical resiniferatoxin, a capsaicin analogue: long term results for the treatment of detrusor hyperreflexia. Eur: Um]. (2000) 38:444–452.
   PubMed Web of Science ®Google Scholar
• •Study demonstrating the long-lasting effects of resiniferotoxin.
   Google Scholar
• CRUZ F, SILVA C: Can desensitisation of bladder sensory fibers relieve urinary symptoms in patients with detrusor instability? Preliminary report with intravesical resiniferatoxin. Neurourol Urodyn. (2000) 19:379–380.
   PubMedGoogle Scholar
• SILVA C, AVELINO A, SOUTO-MOURA C et al: A light and electron microscope histopathological study of the human bladder mucosa after intravesical resiniferatoxin application. BIU Int. (2001) 88:1–6.
   Google Scholar
• DASGUPTA P, CHANDIRAMANI V, PARKINSON MC et al.: Treating the human bladder with capsaicin: is it safe? Eur. Um]. (1998) 33:28–31.
   Google Scholar
• FOVAEUS M, FUJIWARA M, HOGESTATT ED, PERSSON K, ANDERSSON KE: A non-nitrergic smooth muscle relaxant factor released from rat urinary bladder by muscarinic receptor stimulation. Um]. (1999) 161:649–655.
   Google Scholar
• CHAIYAPRASITHI B, MANG CE KILBINGER H, HOFENFELLNER M: Inhibition of human detrusor contraction by a urothelium derived factor." Um]. (2003) 170:1897–1900.
   Google Scholar
• FERGUSON DR, KENNEDY I, BURTON TJ: ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes - a possible sensory mechanism. " Physiol (1997) 505:503–511.
   PubMed Web of Science ®Google Scholar
• •Study showing the release of ATP when the urotheliurn is stretched.
   Google Scholar
• BURNSTOCK G: Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. Anat. (1999) 194:335–342.
   PubMedGoogle Scholar
• PANDITA RK, ANDERSSON KE: Intravesical ATP stimulates the micturition reflex in awake, freely moving rats. Um]. (2002) 168:1230–1234.
   Google Scholar
• COCKAYNE DA, HAMILTON SG, ZHU QM et al: Urinary bladder hyporeflexia and pain-related behaviour in P2X3-deficient mice. Nature (2000) 407:1011–1015.
   PubMed Web of Science ®Google Scholar
• ••Evidence for the role of ATP inmechanosensory mechanisms. los. O'REILLY BA, KOSAKA AH, KNIGHT GF et al.: P2X receptors and their role in female idiopathic detrusor instability. Um]. (2002) 167:157–164.
   Google Scholar
• YOSHIDA M, INADOME A, MURAKAMI S et al.: Effects of age and bladder stretching on non-neuronal acetylcholine release from human bladder. Um]. (2003) 169(4)(Suppl.):316.
   Google Scholar
• DE GROAT WC: A neurologic basis for the overactive bladder. Urology (1997) 50(Suppl. 6A):36–52.
   Google Scholar
• YOKOYAMA O, YOSHIYAMA M, HAMIKI M et al.: Role of the forebrain in bladder overactivity following cerebral infarction in the rat. Exp. Neurol (2000) 163(2):469–476.
   PubMedGoogle Scholar
• YOKOYAMA O, YOSHIYAMA M, HAMIKI M, DE GROAT WC: Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am.,/ Physiol (1999) 276(4):R935–R942.
   Google Scholar
• YOKOYAMA O, YOSHIYAMA M, HAMIKI M, DE GROAT WC: Influence of anaesthesia on bladder hyperactivity induced by middle cerebral artery occlusion in the rat. Am." Physiol (1997) 273(6):1900–1907.
   Google Scholar
• PEHRSON R, ANDERSSON KE: Tramadol inhibits detrusor overactivity caused by dopamine receptor stimulation. Um]. (2003) 170(1):272–275.
   Google Scholar
• PANDITA RK, PEHRSON R, CHRISTOPH T, FRIDERICHS E, ANDERSSON KE: Action of tmmadol on the micturition reflex in awake, freely moving rats. &J. Phannacol (2003) 139:741–748.
   Google Scholar
• PEHRSON R, STENMAN E, ANDERSSON KE: Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. Eur. Um]. (2003) 44(4):495–499.
   PubMedGoogle Scholar
• PEHRSON R, ANDERSSON KE: Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. Um]. (2003) 170(1):272–275.
   Google Scholar
• EL-BINDARY EM, ABU EL-NASR LM: Urodynamic changes following intrathecal administration of morphine and fentanyl to dogs. East. Mediterc Health j (2001) 7(1-2):189–196.
   PubMedGoogle Scholar
• HERPERGER LJ: Postoperative urinary retention in a dog following morphine with bupivacaine epidural analgesia. Can. Vet. J. (1998) 39(10):650–652.
   PubMedGoogle Scholar
• DAS UG, SASIDHARAN P: Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports. Pediatrics (2001) 108(4):1012–1015.
   PubMed Web of Science ®Google Scholar
• MALINOVSKY JM, LE NORMAND L, LEPAGE JY et al.: The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth. Analg. (1998) 87(2):456–461.
   PubMed Web of Science ®Google Scholar
• GENTILI M, BONNET F: Spinal clonidine produces less urinary retention than spinal morphine. Br: J. Anaesthesia (1996) 76(6):872–873.
   PubMedGoogle Scholar
• MALINOVSKY JM, LEPAGE JY, KARAM G, PINAUD M: Nalbuphine reverses urinary effects of epidural morphine: a case report. Clin. Anesth. (2002) 14(7):535–538.
   Google Scholar
• BATRA YK, GILL PK, VAIDYANATHAN S, AGGARWAL A: Effect of epidural buprenorphine and clonidine on vesical functions in women. Intl Clin. Pharinacol Ther. (1996) 34(7):309–311.
   PubMedGoogle Scholar
• SHIMIZU I, KAWASHIMA K, ISHII D, OKU S, KOHAYAKAWA H, OKA M: Pharmacological actions of AH-9700 on micturition reflex in anesthetized rats. Eur. Pharinacol (2001) 412(2):171–179.
   PubMedGoogle Scholar
• CHIEN CT, YU HJ, LIN TB et al: Substance P via NK-1 receptor facilitates hyperactive bladder afferent signaling via action on ROS. Am. J. Physic] (2003) 284(4):F840–F851.
   Google Scholar
• ISHIGOOKA M, ZERMANN DH, DOGGWEILER R, SCHMIDT RA, HASHIMOTO T, NAKADA T: Spinal NK1 receptor is upregulated after chronic bladder irritation. Pain (2001) 93(1):43–50.
   PubMedGoogle Scholar
• ABDEL-GAWAD M, DION SB, ELHILALI MM: Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats. Um]. (2001) 165(5):1739–1744.
   Google Scholar
• JOLLYS JV, JOLLYS JC, WILSON J et al: Does sexual equality extend to urinary symptoms? Neurourol Urodyn. (1993) 12:391–392.
   Google Scholar
• LEPOR H, MACHI G: Comparison of the AUA symptom index in unselected males and females between 55 and 79 years of age. Urology (1993) 42:36–40.
   PubMed Web of Science ®Google Scholar
• SERELS S, STEIN M: Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn. (1998) 17:31–36.
   PubMed Web of Science ®Google Scholar
• SCHWINN DA, PRICE RR: Molecular pharmacology of human aradrenergic receptors: unique features of the al-subtype. Ear: Um]. (1999) 36\(Supp1.1):7–10.
   Google Scholar
• PERLBERG S, CAINE M: Adrenergic response of bladder muscle in prostatic obstruction. Urology (1982) 20:524–537.
   PubMed Web of Science ®Google Scholar
• SMITH DJ, CHAPPLE CR: In vitro response of human bladder smooth muscle in unstable obstructed male bladders: a study of pathophysiological causes. Neurourol Urodyn. (1994) 13:14–15.
   Google Scholar
• ISHIZUKA O, PERSSON K, MATTIASSON A et al.: Micturition in conscious rats with and without bladder outlet obstruction: role of spinal aradrenoceptors. Br: J. Pharmacol (1996) 117:962–966.
   PubMed Web of Science ®Google Scholar
• SMITH MS, SCHAMBRA UB, WILSON KH et al.: al-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding aradrenergic receptor subtypes at four distinct levels. Ma Brain Res. (1999) 63:254–261.
   Web of Science ®Google Scholar
• PERSSON K, PANDITA RK, SPITSBERGEN JM et al.: Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am. J. Physic] (1998) 275:R1366–R1373.
   Google Scholar
• MIZUKAWA K: The segmental detailed topographical distribution of monoaminergic terminals and their pathways in the spinal cord of the cat. Anat. Anz. (1980) 147:125–144.
   PubMedGoogle Scholar
• BOWKER RM, VVESTLLUND KN, COULTER JD: Origins of serotonergic projections to the spinal cord in rat: an immunocytochemical-retrograde transport study. Brain Res. (1981) 226:187–199.
   PubMed Web of Science ®Google Scholar
• KENELLY MJ, RUDY DC: Serotonergic modulation of detrusor hyperreflexia associated with suprasacral spinal cord injury in the unanaesthetized rat: effects of intrathecal 5-hydroxytrypramine and cyproheptadine. I Um]. (1996) 155:600A.
   Google Scholar
• KAKIZAKI H, YOSHIYAMA M, KOYANAGI T et al: Effects of WAY100635, a selective 5-HTIA receptor antagonist on the micturition-reflex pathway in the rat. Am. I Physiol (2001) 280:R1407–R1413.
   Google Scholar
• THOR KB, KATOFIASC MA, DANUSER H, SPRINGER J, SCHAUS JM: The role of 5-HTIA receptors in control of lower urinary tract function in cats. Brant Res. (2002) 946:290–297.
   PubMedGoogle Scholar
• THOR KB, KATOFIASC MA: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anaesthetized female cat. I Pharmacol Exp. Ther. (1996) 274:1014–1024.
   Google Scholar
• KATOFIASC MA, NISSEN J, AUDIA JE, THOR KB: Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Se/. (2002) 71:1227–1236.
   PubMed Web of Science ®Google Scholar